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Abstract 
 
Cellular systems implanted into an injured nerve may produce growth factors or extracellular matrix 
molecules, modulate the inflammatory process and eventually improve nerve regeneration. In the present 
study, we evaluated the therapeutic value of human umbilical cord matrix MSCs (HMSCs) on rat sciatic 
nerve after axonotmesis injury associated to Vivosorbs membrane. During HMSCs expansion and 
differentiation in neuroglial-like cells, the culture medium was collected at 48, 72 and 96 h for nuclear 
magnetic resonance (NMR) analysis in order to evaluate the metabolic profile. To correlate the HMSCs 
ability to differentiate and survival capacity in the presence of the Vivosorbs membrane, the [Ca
2þ
 ]i of 
undifferentiated HMSCs or neuroglial-differentiated HMSCs was determined by the epifluorescence 
technique using the Fura-2AM probe. The Vivosorbs membrane proved to be adequate and used as scaffold 
associated with undiffer-entiated HMSCs or neuroglial-differentiated HMSCs. In vivo testing was carried 
out in adult rats where a sciatic nerve axonotmesis injury was treated with undifferentiated HMSCs or 
neuroglial differentiated HMSCs with or without the Vivosorbs membrane. Motor and sensory functional 
recovery was evaluated throughout a healing period of 12 weeks using sciatic functional index (SFI), 
extensor postural thrust (EPT), and withdrawal reflex latency (WRL). 
Stereological analysis was carried out on regenerated nerve fibers. In vitro investigation showed the 
formation of typical neuroglial cells after differentiation, which were positively stained for the typical 
specific neuroglial markers such as the GFAP, the GAP-43 and NeuN. 
NMR showed clear evidence that HMSCs expansion is glycolysis-dependent but their differentiation 
requires the switch of the metabolic profile to oxidative metabolism. In vivo studies showed enhanced 
recovery of motor and sensory function in animals treated with transplanted undifferentiated and differ-
entiated HMSCs that was accompanied by an increase in myelin sheath. Taken together, HMSC from the 
umbilical cord Wharton jelly might be useful for improving the clinical outcome after peripheral nerve 
lesion.  
 
1. Introduction  
 
A full understanding of nerve regeneration, especially com-plete functional achievement and organ 
reinnervation after nerve injury, still remain the principle goal of regenerative medicine. The reliability of 
animal models is crucial for peripheral nerve research. Because of its peripheral nerve size, the rat sciatic 
nerve has been the most commonly experimental model used in studies concerning the peripheral nerve 
regeneration and possible thera-peutic approaches ( Ronchi et al., 2009). Although sciatic nerve injuries are 
rare in humans, this experimental model provides a very realistic testing bench for lesions involving 
plurifascicular mixed nerves with axons of different size and type competing to reach and reinnervate distal 
targets ( Amado et al., 2008;  Mackinnon et al., 1985). Focal crush causes axonal interruption but preserves 
the connective sheaths (axonotmesis). After this kind of injury, regeneration is usually successful, in a short 
latency (1–2 days), axons regenerate at a steady rate along the distal nerve supported by the reactive 
Schwann cells (SCs) and the preserved endoneural tubules which enhance axonal elongation and facilitate 
adequate reinnervation ( Luis et al., 2007). 
 
Tissue engineering of peripheral nerves associates biomaterials, like chitosan, PLC, and other 
biomaterials, some of them, previously studied by our group ( Amado et al., 2008;  Luis et al., 2008a;  
Maurı´cio  et al., 2011) to cellular systems, able to differentiate into neuroglial like cells or even by 
modulating the inflammatory process, which might improve nerve regeneration, in terms of motor and 
sensory recovery, and also, by shortening the healing period avoiding regional muscular atrophy. Cell 
transplantation has been proposed as a method of improving peripheral nerve regeneration ( Chen et al.,  
2007). SCs, MSCs, embryonic stem cells, marrow stromal cells are the most studied support cells 
candidates. Schwann cell transplantation enhances axon outgrowth both in vitro ( Schlosshauer et al., 2003) 
and in vivo ( Keilhoff et al., 2006). Transplantation of viable SCs offers better results than the sheer release 
of growth factors, because SCs have the above mentioned regeneration promoting effect ( Bhatheja  and 
Field, 2006;  Fansa et al., 1999;  Hall, 1978;  Ide, 1996;  Madduri  and Gander, 2010;  Muir, 2010;  
Schmitte et al., 2010). The generation of sufficient amounts of SCs for auto-transplantation, however, 
requires a significant time for cell culture. Current concepts include mitogenic substances to enhance cell 
yield. Due to their side effects they should be avoided in clinical therapy. Moreover, functional nerves have 
to be sacrificed as SCs donor resulting in loss of sensation, scarring and, possibly, neuroma formation. The 
limitations of harvesting autologous SCs, such as donor nerve sacrifice and donor site morbidity, have led 
to investigation of other cell types that provide similar trophic support to axon regeneration ( Ladak  et al., 
2011). 
 
On the other hand, MSCs have become one of the most interesting targets for Tissue Regeneration 
including the periph-eral nerves. Like bone marrow stromal cells and other mesench-ymal cells, they are 
plastic adherent, stain positively for markers of the mesenchymal (CD10, CD13, CD29, CD44, CD90, and 
CD105) and negatively for markers of the hematopoietic lineage ( Wang  et al., 2004). These cells are 
capable of self-renewal with sustained proliferation in vitro and can differentiate into multiple mesodermal 
cells, including neuron-like cells ( Park et al., 2010). The high plasticity and low immunogenicity of these 
cells, turn them into a desirable form of cell therapy for the injured nervous system without requiring the 
use of immunosuppressive drugs during the treatments ( Thuret et al., 2006). MSCs have been isolated from 
various other origins, including skin, hair follicle, periosteum, amniotic fluid, umbilical cord blood and 
adipose tissue. Harvest and expansion of MSCs are straight forward techniques ( Colter, 2000;  Gnecchi and 
Melo, 2009), which are not only feasible regarding the laboratory approach but also regarding their 
application with the patient. With appropriate stimuli and environmental conditions MSCs exhibit a 
respectable plasticity ( Joshi and Enver, 2002). They may even differentiate into non-mesenchymal 
lineages, including myelinating cells of the peripheral nervous system (PNS) ( Dezawa et al., 2001;  Tohill 
et al., 2004). Beside their easy expansion in culture their plasticity makes MSCs an ideal source for tissue 
repair and tissue engineering. Bone marrow represents the most commonly used tissue source of adult 
MSCs. Bone marrow MSCs (BMSCs) have been applied for cell based therapies; however, due to the 
limited  number of BMSCs available for autologous use and the possibility of donor site morbidity and the 
decreased number of BMSCs along the adult life, there is a need to identify alternative MSCs sources.  
A recently reported potential alternative tissue source of MSCs is the connective tissue (Wharton’s Jelly) 
of human umbilical cord (UC). Different harvesting procedures have led to UC-derived cells that exhibit a 
neuronal phenotype ( Fu et al., 2006;  Mitchell et al.,  2003;  Sarugaser et al., 2005;  Wang et al., 2004) and 
have potential utility in treatment of neurodegenerative diseases ( Weiss et al.,  2003,  2006), indicating the 
versatility of this cell source. Inter-estingly, these cells, which are major histocompatibility complex (MHC) 
class II negative, not only express immunoprivileged and immunomodulatory phenotype, but also their 
MHC class I expres-sion levels can be manipulated ( Sarugaser et al., 2005), making them a potential cell 
source for MSC-based therapies. In addition, these cells represent a non controversial source of primitive 
mesenchymal progenitor cells that can be harvested after birth, cryogenically stored, thawed, and expanded 
for therapeutic uses ( Maurı´cio et al., 2011). 
 
The aim of this study was to explore the therapeutic value of human UC matrix (Wharton’s jelly) derived 
MSCs (HMSC) both in vitro and in vivo, associated to a Poly(DL-lactide-e-caprolactone) PLC (Vivosorbs) 
membrane, on a rat sciatic nerve axonotmesis experimental model. 
 
 
2. Materials and methods 
 
2.1.  Poly(DL-lactide-e-caprolactone) (PLC) membranes 
 
Poly(DL-lactide-e-caprolactone) (PLC) membranes (Vivosorbs) were purchased from Polyganics BV, 
Groningen, Netherlands (FS01-006/20 Lot: FSA2009092311). 
 
2.2. Cell culture and in vitro differentiation of HMSC from Wharton’s jelly umbilical cord 
 
Human MSC from Wharton’s jelly UC (HMSCs) were purchased from PromoCell GmbH (C-12971, lot-
number: 8082606.7). Cryo-preservated cells were cultured and maintained in a humidified atmosphere with 
5% CO2 at 37 1C. Mesenchymal Stem Cell Medium (PromoCell, C-28010) was replaced every 48 h. At 
90% confluence, cells were harvested with 0.25% trypsin with EDTA (Gibco) and passed into a new flask 
for further expansion. HMSCs at a concentration of 2500 cell/ml were cultured and after 24 h cells 
exhibited 30–40% confluence. Differentiation was induced with MSC neurogenic medium (Promocell, C-
28015). Medium was replaced every 24 h for 3 days. The formation of neuroglial-like cells was observed 
after 24 h in an inverted microscope (Zeiss, Germany). 
 
Intracellular free Ca2 þ concentration ([Ca2 þ ]i) was measured in Fura-2-loaded cells by using dual 
wavelength spectrofluorometry as previously described ( Amado et al., 2008). The measurements were 
performed on undifferentiated HMSCs after confluence was obtained and on neuroglial-differentiated 
HMSCs, cultured on Vivosorbs discs in order to correlate the HMSCs ability to differ-entiate and survival 
capacity in the presence of the Vivosorbs membrane. 
 
2.3.  Cytogenetic analysis of human MSC from Wharton’s jelly 
 
HMSC cell line (differentiated) from Wharton’s jelly was studied for cytogenetic analysis at passage 5. 
When confluence was reached, culture medium was changed and supplemented with 4 mg/ml colcemid 
solution (stock solution, Cat. No. 15212-012, Gibco). After 4 h, HMSCs were collected and suspended in,8 
ml of 0.075 M KCl solution supplemented with bovine fetal serum (BFS). Then the suspension was 
incubated at 37 1C for 35 min. After centrifugation (1500 rpm), 8 ml of the fixative methanol: glacial acetic 
acid at 6:1 was added and mixed together, and the cells were again centrifuged. Aftertwo rounds of fixation, 
two new rounds were performed with the fixative methanol: glacial acetic acid at 3:1. After the last 
centrifugation, the HMSC suspension was spread onto very well glass cleaned slides. Analysis was 
performed by one scorer on Giemsa-stained cells. 
 
 
2.4.  Immunocytochemistry 
 
At passage 3, HMSCs were trypsinized, washed and re-suspended in Mesenchymal Stem Cell Medium 
(PromoCell, C-28010) at a concentration of 1 _ 105 cell/ml. HMSCs were fixed with parafor-maldehyde at 
4 1C for 15 min and washed with distilled water before permeabilization in 0.5% Triton-X100. Non-
specific binding was blocked using blocking solution (PBS containing 1% bovine serum albumin (BSA)) 
for 1 h at room temperature. HMSCs were then incubated for 2 h at room temperature with primary 
antibodies of rabbit anti-growth associated protein-43 (GAP-43, 1:200) (Chemicon, AB5220), rabbit anti-
glial fibrillary acidic protein (GFAP, 1:500) (Chemicon, AB5804) and mouse anti-neuronal nuclei (NeuN, 
1:100) (Chemicon, MAB377). After washing, HMSCs were incubated 15 min with secondary antibodies 
goat anti-rat IgG (Millipore, AP136P) and goat anti-rabbit IgG (Millipore, 12-348MN). After several 
washes in PBS, HMSCs were incubated with horseradish peroxidase (HRP)-coupled streptavidin for 10 
min. DAB (diamino-benzidine) served as chromogen. 
 
 
2.5.  NMR spectroscopy 
 
During HMSCs expansion and differentiation to neuroglial-like cells, 160 mL of the culture medium was 
collected at 48, 72 and 96 h (N¼5) for nuclear magnetic resonance (NMR) analysis. 1 H-NMR spectra of 
the collected samples were acquired at 14.1 T, 25 1C, using a Varian 600 MHz spectrometer equipped with 
a 3 mm indirect detection probe with z-gradient (Varian, Palo Alto, CA) by standard methods. Solvent-
suppressed 1 H-NMR spectra were acquired with 6 kHz sweep width, using 14 s delay for allowing total 
proton relaxation, 3 s water pre-saturation, 451 pulse angle, 3.5 s acquisition time, and at least 64 scans. 1H-
NMR spectroscopy was performed and the following metabolites were determined: lactate, doublet located 
at 1.33 ppm; alanine, doublet at 1.45 ppm; and H1-a glucose, doublet at 5.22 ppm. Sodium fumarate (final 
concentration of 2 mM) was used as an internal reference (6.50 ppm) to quantify metabolites in solution. 
The relative areas of 1 H-NMR resonances were quantified using the curve-fitting routine supplied with the 
NUTSproTM NMR spectral analysis program (Acorn, NMR Inc, Fremont, CA). 
 
2.6.  Surgical procedure 
 
For the in vivo testing, Sasco Sprague adult rats (Charles River Laboratories, Barcelona, Spain) were 
divided in groups of 6 animals each: a group of 6 animals was used as control without any sciatic nerve 
injury (Group 1 – Control). In Group 2 the crushed sciatic nerve did not have any other intervention (Group 
2 – Crush). In Group 3, the axonotmesis lesion of 3 mm was enwrapped with a PLC (Vivosorbs) membrane 
(Group 3 – CrushPLC). In Group 4, the crushed sciatic nerve was infiltrated in the lesion area with a 
suspension of 1500 HMSCs (in a total volume of 50 ml) (Group 4 – CrushCell), in Group 5, the crushed 
sciatic nerve was encircled by a PLC (Vivosorbs) membrane covered with a monolayer of non (Group 5 – 
CrushCellNonDifPLC) and in Group 6 the axonotmesis lesion of 3 mm was enwrapped with a PLC 
(Vivosorbs) membrane covered with a monolayer of differentiated HMSCs (neuroglial-like cells) (Group 6 
– CrushCell-DifPLC). The standardized crush injury was carried out with the animals placed prone under 
sterile conditions and the skin from the clipped lateral right thigh scrubbed in a routine fashion with 
antiseptic solution. The surgery procedure was the one previously described ( Luı´s et al., 2007;  Luis et al., 
2007). The standard crush injury was performed by a non-serrated clamp (Institute of Industrial Electronic 
and Material Sciences, University of Tech-nology, Vienna, Austria), exerting a constant force of 54 N for a 
period of 30 s, 10 mm above the bifurcation into tibial and common peroneal nerves inducing a 3 mm 
axonotmesis lesion. To prevent autotomy, a deterrent substance was applied to rat right foot. No local or 
systemic signs of rejection or foreign body were observed in the experimental animals transplanted with 
PLC membranes and HMSCs. There was no need of administrating immunosuppressive treatment to the 
experimental animals during the entire healing period of 12 weeks after the surgical procedure. 
 
2.7.  Functional assessment 
 
All animals were tested preoperatively (week 0), and every week until the end of the 12-week follow-up 
time. 
 
 
2.7.1.  Motor performance and nociceptive function  
Motor performance and nociceptive function were evaluated by measuring extensor postural thrust (EPT) 
and withdrawal reflex latency (WRL), respectively ( Luis et al., 2007,  2008a,  b). For EPT test, the affected 
and normal limbs were tested 3 times, with an interval of 2 min between consecutive tests, and the 3 values 
were averaged to obtain a final result. The normal (unaffected limb) EPT (NEPT) and experimental EPT 
(EEPT) values were incorporated into an equation (Eq. (1)) to derive the percentage of functional deficit, as 
described in the literature( Koka and Hadlock, 2001) 
 
%Motor deficit ¼ ½ð NEPT2EEPTÞ=NEPT&100 ð1Þ  
The nociceptive withdrawal reflex (WRL) was adapted from the hotplate test developed by  Masters et al. 
(1993) and described elsewhere ( Luis et al., 2007,  2008a,  b). Normal rats withdraw their paws from the 
hotplate within 4 s or less ( Hu et al., 1997). The cutoff time for heat stimulation was set at 12 s to avoid 
skin damage to the foot ( Varejao et al., 2003). 
 
2.7.2.  Sciatic functional index (SFI)  
For SFI, animals were tested in a confined walkway measuring 42 cm long and 8.2 cm wide, with a dark 
shelter at the end, as previously described ( Luis et al., 2007,  2008a,  b). Several mea-surements were taken 
from the footprints: (i) distance from the heel to the third toe, the print length (PL); (ii) distance from the 
first to the fifth toe, the toe spread (TS); and (iii) distance from the second to the fourth toe, the 
intermediary toe spread (ITS). For SFI, all measurements were taken from the experimental  
(E) and normal (N) sides. The mean distances of three measure-ments were used to calculate the following 
factors: 
 
Toe spread factor (TSF)¼(ETS – NTS)/NTS 
Intermediate toe spread factor (ITSF)¼(EITS – NITS)/NITS Print length factor (PLF)¼(EPL – NPL)/ 
NPL  
SFI was calculated as described by  Bain et al., (1989) according to the following equation: 
 
SFI ¼ _38:3ð EPL2NPLÞ=NPLþ109:5ð ETS2NTSÞ=NTS 
þ13:3 ðEIT2NITÞ=NIT28:8 ¼ ð _38:3 _ PLFÞ 
þð109:5 _ TSFÞþð13:3 _ ITSFÞ28:8 ð2Þ 
  
For SFI, an index score of 0 is considered normal and an index of _100 indicates total impairment. When 
no footprints were measurable, the index score of _100 was given ( Dijkstra et al.,  2000). 
 
 
 
2.8.  Sciatic nerve stereology 
 
Nerve samples (10-mm-long sciatic nerve segments distal to the crush site and from un-operated 
controls) were processed for quantitative morphometry of myelinated nerve fibers ( Raimondo  et al., 2009). 
Fixation was carried out using 2.5% purified glutar-aldehyde and 0.5% saccarose in 0.1 M Sorensen 
phosphate buffer for 6-8 hours and resin embedding was obtained following Glauerts’ procedure ( Scipio et 
al., 2008). Series of 2-mm thick semi-thin transverse sections were cut using a Leica Ultracut UCT 
ultramicrotome (Leica Microsystems, Wetzlar, Germany) and stained by Toluidine blue. Stereology was 
carried out on a DM4000B microscope equipped with a DFC320 digital camera and an IM50 image 
manager system (Leica Microsystems, Wetzlar, Germany). Systematic random sampling and D-disector 
were adopted using a protocol previously described ( Geuna et al.,  2000,  2004). Fiber density and total 
number of myelinated fibers were estimated together with fiber and axon diameter and myelin thickness. 
 
 
2.9.  Statistical analysis 
 
Data of functional tests are reports as means and standard deviations (SD) at each time point, including 
pre-operatively, and each experimental group. Differences between time points and between groups were 
tested by two-way analysis of variance (ANOVA) using a mixed model of within (time of recovery) and 
between-subjects (experimental groups) factors. In cases of significant main effect of experimental group 
(between-subjects factor), pairwise comparisons were further conducted using the post hoc Tukey’s HSD 
test using IBM SPSS statistics19 software package (SPSS, Inc.). For stereology, statistical comparisons of 
quantitative data were subjected to one-way ANOVA test using the software ‘‘Statistica per disci-pline bio-
mediche’’ (McGraw-Hill, Milan, Italy). In RMN studies, comparison of data between different 
experimental groups was performed by One-way ANOVA followed by Newman– Keuls post-hoc test using 
GraphPad Prism Software, (San Diego California USA). In all cases differences at p o0.05 were con-sidered 
significant. 
 
3.  Results 
 
3.1. Cytocompatibility of Vivosorbs membranes and confirmation of HMSCs differentiation 
into neuroglial-like cells and karyotype analysis. 
 
Results obtained from epifluorescence technique are referred to measurements from undifferentiated 
HMSCs and neuroglial-differentiated HMSCs which correspond to [Ca2 þ ]i from cells that did not begin 
the apoptosis process (data not shown). The undifferentiated HMSCs cultured on Vivosorbs membranes 
reached confluence and exhibited a normal star-like shape with a flat morphology in culture. In the presence 
of neurogenic medium, the formation of neuroglial-like cells was observed after 24 h. According to these 
results, it is reasonable to conclude that Vivosorbs membranes are a viable substrate for undifferentiated 
HMSCs culture or neuroglial-differentiated HMSCs adhesion, multiplication and differentiation. 
 
The phenotype of HMSCs was assessed by PromoCell. Rigid quality control tests are performed for each 
lot of PromoCell HMSCs isolated from Wharton’s jelly of UC. HMSCs were tested for cell morphology, 
adherence rate and viability. Furthermore, for each cell lot of characterization was characterized by flow 
cytometry analysis for a comprehensive panel of markers, such as PECAM (CD31), HCAM (CD44), CD45, 
and Endoglin (CD105). The HMSCs exhibited a mesenchymal-like shape with a flat and polygonal 
morphology. During the expansion of cells long spindle-shaped and colonized the whole culturing surface 
was observed ( Fig. 1A). After 96 h of culture in neurogenic medium, we observed a morphological change. 
The cells became exceed-ingly long and there was a formation of typical neuroglial-like cells with multi-
branches and secondary branches ( Fig. 1B). The differentiation was tested based on the expression of 
typical neuronal markers such as GFAP, GAP-43 and NeuN in neuroglial-like differentiated MSCs. 
Undifferentiated HMSCs were negatively labeled to GFAP, GAP-43 and NeuN ( Fig. 2A, C and E, 
respectively). After 96 h of differentiation the attained cells were positively stained for glial protein GFAP ( 
Fig. 2B) and for the growth-associated protein GAP-43 ( Fig. 2D). All nuclei of neuroglial-like cells were 
also labeled with the neuron specific nuclear protein NeuN ( Fig. 2E) demonstrating successful 
differentiation of HMSCs in neuroglial-like cells. 
 
Undifferentiated HMSCs exhibited a normal star-like shape with a flat morphology. After in vitro 
differentiation, HMSCs morphology changed into typical neuroglial-like pattern with multi-branches and 
secondary branches ( Fig. 1B). Giemsa-stained cells of differentiated HMSC cell line at passage 5 were 
analyzed for cytogenetic character-ization. However, no metaphases were found, therefore the karyo-type 
could not be established. The karyotype of undifferentiated HMSCs was determined previously and no 
structural alterations were found demonstrating absence of neoplastic characteristics in these cells, as well 
as chromosomal stability to the cell culture procedures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. HMSCs from Wharton’s jelly exhibiting a mesenchymal-like shape with a flat polygonal morphology (A). After72 h of 
culture in neurogenic medium the cells became exceedingly long and there is a formation of typical neuroglial-like cells with 
multibranches. (B) (Magnification: 100x). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Undifferentiated HMSC cells from the Wharton’s jelly presenting a negative staining for: (A) GFAP which is a glial cell 
marker, (C) GAP-43 which is related with axonal outgrowth, and (E) NeuN which is a marker for nucleus of neurons. Neuroglial-
like cells obtained from HMSCs in vitro differentiated with neurogenic medium exhibiting a positive staining for: (B) GFAP, (D) 
GAP-43, and (F) NeuN (Magnification: 200x). 
  
3.2. Glycolysis is stimulated during HMSCs expansion but not during differentiation 
 
During the 96 h expansion of undifferentiated HMSCs, the glucose consumption was 4.470.05 pmol/cell, 
while during differentiation the cells consumed 5.071.1 pmol/cell. Interestingly, although the glucose 
consumption was very similar in both conditions after the 96 h cell culture, the glucose consumption rate 
was only similar between the 48 and 72 h. Undifferentiated HMSCs mostly consumed glucose in the first 
48 h at a rate of 0.570.004 pmol/h/cell/h, while during differentiation, the glucose consumption rate lowered 
to just 0.0870.01 pmol/h/cell/h. Between the 72 and 96 h of culture, the glucose consumption was also 
increased in undifferentiated cells (0.2170.04 pmol/h/cell) when compared with cells undergoing 
differentiation (0.0870.04 pmol/h/cell). As expected, the lactate production increased during HMSCs 
expansion. After 96 hours, the lactate production was 2671.1 pmol/cell during expansion, while during cell 
differentiation the total lactate production was 6.07 0.6 pmol/cell. The lactate production rate during 
HMSCs expansion was increased during the first and last hours of expansion. In the first 48 h, the rate was 
0.270.03 pmol/h/cell and between the 72 and 96 h the rate was 0.570.04 pmol/h/cell. Interestingly, during 
the 96 h of differentiation the lactate production rate was almost stable although between the 48 and 96 h of 
differentiation there was no production but a slight consumption of lactate. 
 
3.3. Lactate and alanine metabolism is altered during differentiation of HMSCs 
 
Alanine production was significantly decreased during HMSCs differentiation. During the 96 h 
expansion, the cells produced 6.97 0.7 pmol/cell while after differentiation the alanine production was 
2.270.4 pmol/cell. During expansion and differentiation, the alanine was mostly produced during the first 
hours as seen by the alanine production rate. During the first 48 h, undifferentiated HMSCs pro-duced 
alanine at a rate of 0.1070.003 pmol/h/cell while during differentiation, in that period, the alanine 
production rate was 0.0270.008 pmol/h/cell. The lactate/alanine ratio was significantly decreased after 48 
and 72 h in undifferentiated HMSCs. The ratio decreases from 3.570.3 at time zero of expansion to 2.170.1 
and 2.570.3 in the following 48 and 72 h, respectively. After 96 h, HMSCs differentiated into neuroglial-
like cells presented a significantly lower lactate/alanine ratio (2.670.5) than undifferentiated cells (3.970.2). 
 
3.4.  Functional analysis 
 
3.4.1. Nociceptive function evaluated by withdrawal reflex latency (WRL)  
The withdrawal reflex requires intact thermal and nociceptive innervations of the hindpaw. Early after 
sciatic axonotmesis, the withdrawal response could not be recorded and WRL values rose to the cutoff time 
of 12 s ( Table 1). WRL progressively reduced approaching the normal values at week 12. There was a 
signifi-cant effect of time in WRL scores during the healing period [F(10,330)¼168.32, p¼0.000]. An 
overall main effect of kind of treatment was also noticed in WRL results during the healing time 
[F(5,33)¼22.786, p¼0.000]. WRL values were significantly different in groups treated with the PLC 
membrane, alone or in combination with undifferentiated and differentiated HMSCs (Group 5 – 
CrushCellNonDifPLC; Group 6 – CrushCellDifPLC; Group 3 – CrushPLC) with the groups not receiving 
the PLC membrane (po0.05). In this case, however, the WRL values seem to indicate better functional 
recovery in the groups with the cellular system (Group 5 – CrushCellNonDifPLC; Group 6 – 
CrushCellDifPLC), demonstrating the positive results concerning the cellular system treatment ( Table 1). 
3.4.2 Motor performance by measuring extensor postural thrust   
(EPT)   
The EPT measures the antigravity response when animals are lowered and the hindlimb is loaded. In 
control animals and before injury, EPT scores center around zero, showing similar forces in both sides. In 
the week following sciatic axonotmesis, EPT scores increased to near maximal values, indicating almost 
complete loss of contractile force in the affected hindlimb. EPT scores then recovered steadily in the 
following weeks to normal values. Therefore, a significant effect of time in EPT scores during the  
 
healing period was found [F(10,330)¼136.09, p¼0.000]. Also, differences in EPT scores between the 
experimental groups were  
 
significant [F(5,33)¼48.678, p¼0.000]. Further pairwise tests showed that the EPT values in the 
untreated axonotomized group (Group 2) were similar to the other axonotomized groups treated with 
different combinations of PLC membranes and cellular systems (Group 5 and Group 6). The groups treated 
with cells and PLC membrane (Group 5 and Group 6), however, presented significant differences in EPT 
values compared to the group treated with PLC membrane only (Group 3) (p o0.05), with positive results 
associated with the cellular system treatment. The group treated with infiltrated undifferentiated HMSCs 
(Group 4) presented worse recovery of EPT values, when compared to the group where these cells (Group 5 
and Group 6) were applied locally, by means of a PLC membrane (po0.05). There were no significant 
differences between the groups with PLC membranes plus undifferentiated and differentiated HMSCs 
(Group 5 and Group 6) ( Table 2).  
 
3.4.3 Sciatic functional index (SFI)   
The SFI score demonstrated severe deficit in the 2 weeks following sciatic nerve crush in all 
experimental groups. In the following weeks, SFI values improved progressively ending up with values 
indistinguishable from control animals by week 12 of recovery. Therefore, a significant main effect of time 
was demon-strated by ANOVA [F(10,330)¼268.937, p¼0.000]. ANOVA also demonstrated a significant 
effect of group [F(5,33)¼52.632, p¼0.000]. Further pairwise comparisons located the group effect in the 
Group 4, with this group displaying delayed recovery of SFI compared to the Group 2 (p¼0.000) and 
Group 2 (p¼0.004) ( Table 3). 
 
3.5.  Sciatic nerve stereology 
 
 Fig. 3 shows the histological appearance of the nerve fibers in the different experimental groups. As 
expected after a crush injury that does not interrupt the nerve continuity, axon re-generation occurred in all 
experimental groups. Results of the  stereological analysis of regenerated nerve fibers are reported in  Table 
4. Statistical analysis showed that all axonotmesis groups have a significantly (po0.05) higher number and 
density of regenerated nerve fibers compared to control. By contrast, in all axonotmesis groups, nerve fibers 
showed a significantly (po0.05) smaller diameter, of both axon and fiber, and myelin thickness. As far as 
numerical differences among axonotmesis groups are concerned, statistical analysis did not reveal any 
significant (p40.05) difference for any of the morphological predictors of nerve recovery except for myelin 
thickness that was significantly (po0.05) higher in Group 5 and Group 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Histological appearance of the regenerated nerve fibers in the different experimental groups: Control (A), Crush (B), 
CrushPLC (C), CrushCell (D), Crush-CellNonDifPLC (E), CrushCellDifPLC (F) (Magnification: 1000x). 
 4.  Discussion 
 
Peripheral nerve tissue engineering associates biomaterials to cellular systems, able to differentiate into 
neuroglial-like cells, which might improve motor and sensory recovery. SCs, MSCs, embryonic stem cells, 
marrow stromal cells are the most studied support cells candidates. The cellular systems implanted into the 
injured nerve may produce growth factors or extracellular matrix (ECM) molecules, or may modulate the 
inflammatory process, to improve nerve regeneration ( Amado et al., 2010;  Gu et al., 2011;  Luis et al., 
2007,  2008a;  Simoes et al., 2010). To implant cultured cells into defective nerves (with axonotmesis and 
neurotmesis injuries), there are two main techniques. The cellular system may be directly injected into the 
neural scaffold which has been interposed between the proximal and distal nerve stumps or around the 
crush injury (in neurotmesis and axonotmesis injuries, respectively). It can also be performed by pre-adding 
the cells to the neural scaffold via injection or co-culture (in most of the cellular systems, it is allowed to 
form a monolayer) and then the biomaterial with the cellular system is implanted in the injured nerve ( 
Maurı´cio et al., 2011). 
 
 
The majority of natural biomaterials used in clinical applications (for instance, peripheral nerve injuries) 
such as hyaluronic acid, collagen, and gelatin are derived from animal sources. In spite of thorough 
purification methods, these materials bear the inherent risk of transfer of viral diseases and may cause 
immunological body reactions while synthetic biomaterials are not associated with these risks ( Maurı´cio et 
al., 2011). Results obtained from epifluorescence technique that measure the [Ca2 þ ]i and the cell culture 
morphology of undifferentiated HMSCs and neuroglial-differentiated HMSCs cul-tured on Vivosorbs 
membranes evidence that this biomaterial is a viable substrate for undifferentiated HMSCs culture or 
neuroglial-differentiated HMSCs adhesion, multiplication and differentiation.  
Our data showed that PLC does not deleteriously interfere with the nerve regeneration process, as a matter 
of fact, the informa-tion on the effectiveness of PLC membranes and tube-guides for allowing nerve 
regeneration was already provided experimentally and with patients ( Maurı´cio et al., 2011). PLC becomes 
hydro-philic by water uptake, which increases the permeability of the polymer. This is important in the 
control of nutrient and other metabolite transport to the surrounding healing tissue. A few weeks after 
implantation, the mechanical strength gradually decreases and loss of molecular weight occurs as a result of 
the hydrolysis process. In approximately 24 months, PLC degrades into lactic acid and hydroxycaproic acid 
which are both safely metabolized into water and carbon dioxide and/or excreted through the urinary tract. 
In contrast to other biodegradable polymers, PCL has the advantage of not creating an acidic and potentially 
disturbing micro-environment, which is favorable to the surrounding tissue ( Luis et al., 2007). 
 
 
Table 4  
Histomorphometrical assessment of normal (Group 1—Control) and regenerated sciatic nerves submitted to a standardized sciatic nerve crush injury with non-serrated clamp (week-12 post-
traumatic). Results are presented as mean and standard deviation (SD). N corresponds to the number of rats within the experimental group (N¼6). 
Group Fiber density (N/mm2) Fiber Number (N) Fiber diameter (lm) Axon diameter (lm) Myelin thickness (lm) 
         
Control 15,905 7287 7666 7 190 6.6670.12 4.2670.07 1.1970.03 
Crush 20,109 71,232 10,644 7 423 4.9970.19 3.4870.10 0.7670.05 
CrushPLC 23,349 74,278 11,532 7 1,086 4.5570.36 3.3670.17 0.6070.10 
CrushCell 20,200 74,971 9806 7 2,695 5.3170.69 3.7470.49 0.7870.10 
CrushCellNondiffPLC 20,945 71,162 10,909 7 1,584 5.1170.42 3.3970.25 0.8670.11 
CrushCellDiffPLC 23,593 75,611 9640 7 1,784 4.9370.43 3.2570.37 0.8470.05 
 
Group 1¼Control (without any sciatic nerve injury), n¼6.  
Group 2¼Crush (axonotmesis injury without any other intervention), n ¼6.  
Group 3¼CrushPLC (axonotmesis lesion of 3 mm enwrapped with a PLC membrane), n ¼7.  
Group 4¼CrushCell (axonotmesis lesion infiltrated with a suspension of 1250-1500 HMSCs), n¼7.  
Group 5¼CrushCellNonDifPLC (axonotmesis lesion of 3 mm enwrapped with a PLC membrane covered with a monolayer of non-differentiated HMSCs), n¼6. Group 
6¼CrushCellDifPLC (axonotmesis lesion of 3 mm enwrapped with a PLC membrane covered with differentiated HMSCs), n ¼7.
 
Extra-embryonic tissues, as stem cell reservoirs, offer many advantages over both embryonic and adult 
stem cell sources. Extra-embryonic tissues, collectively known as the afterbirth, are routinely discarded at 
parturition, so little ethical controversy attends the harvest of the resident stem cells populations. Most 
significantly, the comparatively large volume of extra-embryonic tissues and easy manipulation 
hypothetically increases the number of stem cells that can be isolated ( Marcus and Woodbury, 2008). The 
UC contains two arteries and one vein protected by a proteoglycan rich connective tissue called Wharton’s 
jelly. Within the abundant extracellular matrix of Wharton’s jelly resides a recently described stem cell 
population. In average, 400,000 cells can be isolated per UC, which is significantly greater than the number 
of MSCs that can be routinely isolated from adult bone marrow. In vitro, Wharton’s jelly MSCs cells are 
capable of differentiation to multiple mesoderm cell types including skeletal muscle and neurons ( Fu et al., 
2006;  Wang et al., 2004). Genera-tion of clinically important dopaminergic neurons has also been reported 
( Fu et al., 2006). HMSCs isolated from Wharton’s jelly can be easily and ethically obtained and processed 
compared with embryonic or bone marrow stem cells. These stem cells may be a valuable source in the 
repair of the peripheral nervous system with capacity to differentiate into neuroglial-like cells ( Fu et al.,  
2006;  Yang et al., 2008). The transplanted HMSCs were also able to promote local blood vessel formation 
and release the neuro-trophic factors brain-derived neurotrophic factor (BDNF) and glial cell line-derived 
neurotrophic factor (GDNF) ( Fu et al., 2006;  Wang et al., 2004). Previous results obtained by our research 
group using N1E-115 cells in vitro differentiated into neuroglial-like cells to promote regeneration of 
axonotmesis and neurotm-esis lesions in the rat model showed that there was no significant effect in 
promoting axon regeneration and, when N1E-115 cells were cultured inside a PLGA scaffold used to bridge 
a nerve defect, they can even exert negative effects on nerve fiber regeneration ( Luis et al., 2008a;  
Maurı´cio et al., 2011). The presence of transplanted N1E-115 cells in nerve scaffolds com-peting for the 
local blood supply of nutrients and oxygen and by space-occupying effect could have hindered the positive 
effect of local neurotrophic factor release leading a negative outcome on nerve regeneration ( Amado et al., 
2008,  2010;  Luis et al., 2008a;  Maurı´cio et al., 2011). Thus, N1E-115 cells did not prove to be a suitable 
candidate cellular system for treatment of nerve injury after axonotmesis and neurotmesis ( Amado et al., 
2008,  2010;  Luis et al., 2008a;  Maurı´cio et al., 2011) and their application is limited only to research 
purposes as a basic scientific step for the development of other cell delivery systems, due to its neoplastic 
origin. In this study, we used a PLC membrane to deliver undifferentiated and in vitro differentiated 
HMSCs from the UC Wharton jelly and we compared this delivery approach with direct infiltration of these 
undifferentiated HMSCs in suspension, in the rat sciatic nerve axonotmesis model. The cellular systems 
implanted into the injured nerve may produce growth factors or ECM molecules, or may modulate the 
inflammatory process, to improve nerve regeneration or even replaced the injured neural and SCs ( Amado 
et al., 2008,  2010;  Luis et al., 2008a;  Maurı´cio  et al., 2011). The differentiated HMSCs karyotype could 
not be established, once no dividing cells were obtained at passage 5, which can be in agreement with the 
degree of differentiation. The karyotype analysis of undifferentiated HMSCs previously determined and 
published elsewhere, excluded the presence of neoplastic signs, thus supporting the suitability of our cell 
culture and differentiation procedures. This concern also resulted from our previous experience with N1E-
115 neoplastic cell line and the negative results we obtained in the treatment of axonotmesis and 
neurotmesis injuries ( Amado et al., 2008,  2010;  Luis et al., 2008b;  Maurı´cio et al., 2011). Nevertheless, 
our cultured undifferentiated HMSCs showed normal morphology when inspected with an inverted 
microscope. These cells presented a star-like shape with a flat morphology, characteristic of the MSCs. 
 
A consequence of cell metabolism during in vitro expansion and differentiation is that culture conditions 
are constantly changing. The comprehension and optimization of the expansion and differentiation process 
of HMSCs will contribute to maximi-zation of cell yield, reduction of cell culture and a decrease of total 
process costs ( Gong et al., 2009;  Kirouac and Zandstra, 2008). In culture conditions, cells consume mostly 
glucose as substrate for the generation of cellular energy (ATP). A high rate of glucose consumption is 
necessary for cell growth and maintenance. In fact, it has been proposed that cells undergoing high 
prolifera-tion rates rely essentially on glycolysis to generate ATP, producing considerable amounts of 
lactate ( Vander Heiden et al., 2009). This process, known as Warburg effect, has been described to occur in 
HMSCs during expansion ( Dos Santos et al., 2010;  Funes  et al., 2007). Our results obtained from the in 
vitro testing of this cellular system show that during 96 h expansion, the undiffer-entiated HMSCs 
consumed glucose and produce, as expected, high concentration of lactate as a metabolic sub-product which 
is consistent with the Warburg effect and glycolysis stimulation. It was also described that MSCs do not 
require oxidative phosphor-ylation to survive ( Dos Santos et al., 2010;  Funes et al., 2007) instead, hypoxia 
prolongs the lifespan of these cells, increases their proliferative capacity and reduces differentiation( Fehrer  
et al., 2007). Several studies in recent years investigated the biological activity of HMSCs and their in vitro 
differentiation in neuroglial-like cells ( Fu et al., 2004;  Mitchell et al., 2003). In this study, HMSCs were in 
vitro differentiated with neurogenic med-ium. After 96 h the regular mesenchymal-like shape of the cells 
changed and the cells became exceedingly long. Morphologically it was observed the formation of 
neuroglial-like cells after differentiation which were positively stained for the typical specific neuronal 
markers ( Choong et al., 2007;  Fu et al., 2004;  Mitchell et al., 2003) such as the GFAP, the GAP-43 and 
the NeuN attesting a clear successful differentiation. The morphologic and biochemical characteristics of 
neuroglial-like cells are already described but the mechanism by which stem cells differentiate into 
neuroglial-like cells is still unknown. In our experimental conditions, HMSCs that undergo differentiation 
in neuroglial-like cells, consumed significantly less glucose and produced signifi-cantly less lactate than 
HMSCs that undergo expansion. These major differences allow us to conclude that during HMSCs 
differentiation in neuroglial-like cells the glycolytic process, which proved to be the crucial metabolic 
mechanism during HMSCs expansion, is switched to oxidative metabolism. Several factors, such as 
inhibition of oxidative phosphorylation due to defects in mitochondrial DNA, dysfunctional Krebs cycle, or 
inactivation of p53 have been suggested to contribute to the glycolytic switch occurr during cellular 
expansion and differen-tiation ( Funes et al., 2007). Recently, it has been shown that umbilical-cord derived 
mesenchymal stem cells adapt their oxygen consumption and energy metabolism to the available oxygen 
concentrations ( Lavrentieva et al., 2010). In our conditions, HMSCs consumed glucose at higher rates 
during the first 48 h of expansion. After that period the glucose consumption rate decreases although there 
was no reduction in lactate production rate. Interestingly, during HMSCs differentiation in neuroglial-like 
cells, lactate production rate is significantly lower and between 72 and 96 h, there was no lactate production 
rate but rather consumption. The conversion of pyruvate in lactate is an NADH-dependent reduction but 
pyruvate may also be converted into alanine via transaminase reaction, through the enzyme alanine  
aminotransaminase ( Yang et al., 2002). Surprisingly, during HMSCs expansion, the alanine production 
significantly increased but the same was not noted during differentiation in neuroglial-like cells. However, 
the lactate/alanine ratio was lower at 48 and 72 h during HMSCs expansion than at the same periods of 
differentiation. After 96 h this ratio was decreased in differen-tiated cells. The appearance of more alanine 
than lactate in the media of neuroglial-like cells can be associated with a reduced redox cytosolic state (low 
ratio NADH/NADþ) which may point to a role of oxidative stress during the differentiation of HMSCs in 
neuroglial-like cells, however further investigation is needed to prove this suggestion. Our results show 
clear evidences that HMSCs expansion is dependent of glycolysis while their differ-entiation in neuroglial-
like cells requires the switch of the metabolic profile to oxidative metabolism. Also important may be the 
role of oxidative stress during this process. 
 
Here we also tested the efficacy of our combined biomaterial and cellular system approach in the in vivo 
treatment of sciatic nerve crush injury. Following transection, axons show staggered regeneration and may 
take substantial time to actually cross the injury site and enter the distal nerve stump ( Brushart et al., 2002). 
Although delayed axonal elongation might be caused by growth inhibition originating from the distal nerve 
itself, growth-stimu-lating influences may overcome axons stagger. More robust and fast nerve regeneration 
is expected to result in better reinnerva-tion and functional recovery. As a potential source of growth 
promoting signals, HMSCs transplantation is expected to have a positive outcome. Our results showed that 
the use of either undifferentiated or differentiated HMSCs enhanced the recovery of sensory and motor 
function. The observation that in both cell-enriched experimental groups myelin sheath was thicker, suggest 
that HMSCs might exert their positive effects on SCs, the key element in Wallerian degeneration and the 
following axonal regeneration ( Geuna et al., 2009). 
 
 
5.  Conclusion 
 
We conclude that HMSCs isolated from the Wharton’s jelly of the UC delivered through PLC 
membranes might thus be regarded a potentially valuable tool to improve clinical outcome especially after 
trauma to sensory nerves, such as digital nerves. In addition, these cells represent a non controversial source 
of primitive mesenchymal progenitor cells that can be harvested after birth, cryogenically stored, thawed, 
and expanded for therapeutic uses, including nerve injuries like axonotmesis and neurotmesis. 
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